Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Therapy Perspectives
Published in: Drugs & Therapy Perspectives 3/2024

11-03-2024 | Mood Disorders | Practical Issues and Updates

Treat bipolar depression with atypical antipsychotics and mood stabilisers; new therapies require further study

Author: Simon Fung

Published in: Drugs & Therapy Perspectives | Issue 3/2024

Login to get access

Abstract

Patients with bipolar disorder frequently suffer from episodes of depression, which is a major cause of morbidity. A range of atypical antipsychotics and mood stabilisers are recommended in guidelines for the treatment of bipolar depression but there is no consensus on which therapies should be used in the first line. Many patients remain symptomatic and experience relapse despite treatment. Pharmacotherapies with efficacy in other depressive disorders and those with novel mechanisms of action (including those targeting neuronal plasticity, inflammation, mitochondrial function) are currently being investigated for efficacy in bipolar depression.
Literature
1.
McIntyre RS, Calabrese JR. Bipolar depression: the clinical characteristics and unmet needs of a complex disorder. Curr Med Res Opin. 2019;35(11):1993–2005.CrossRefPubMed
2.
3.
Tondo L, Vázquez GH, Baldessarini RJ. Options for pharmacological treatment of refractory bipolar depression. Curr Psychiatry Rep. 2014;16:431.CrossRefPubMed
4.
Keramatian K, Chakrabarty T, DuBois A, et al. New pharmacologic approaches to the treatment of bipolar depression. Drugs. 2023;83(10):843–63.CrossRefPubMed
5.
Malhi GS, Bell E, Boyce P, et al. The 2020 Royal Australian and New Zealand College of psychiatrists clinical practice guidelines for mood disorders: bipolar disorder summary. Bipolar Disord. 2020;22(8):805–21.CrossRefPubMed
6.
National Institute for Health and Care Excellence. Bipolar disorder: the assessment and management of bipolar disorder (2023 updated edition). 2014. https://​www.​nice.​org.​uk/​. Accessed 22 Dec 2023.
7.
Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20:97–170.CrossRefPubMedPubMedCentral
8.
Bschor T, Baethge C, Grunze H, et al. S3-Leitlinie Bipolare Störungen – 1. Update 2019 Was ist neu in der Pharmakotherapie? [German S3 guidelines on bipolar disorders-first update 2019: what is new in pharmacotherapy?]. Nervenarzt. 2020;91(3):216–21.CrossRefPubMed
9.
Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356(17):1711–22.CrossRefPubMed
10.
Yalin N, Young AH. Pharmacological treatment of bipolar depression: what are the current and emerging options? Neuropsychiatr Dis Treat. 2020;16:1459–72.CrossRefPubMedPubMedCentral
11.
Bahji A, Ermacora D, Stephenson C, et al. Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: a systematic review and network meta-analysis. J Affect Disord. 2020;269:154–84.CrossRefPubMed
12.
Calabrese JR, Durgam S, Satlin A, et al. Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: a phase 3 randomized placebo-controlled trial. Am J Psychiatry. 2021;178:1098–106.CrossRefPubMed
13.
Suppes T, Durgam S, Kozauer SG, et al. Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: results from a randomized placebo-controlled clinical trial. Bipolar Disord. 2023;25(6):478–88.CrossRefPubMed
14.
Yatham LN, Vieta E, Earley W. Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial. Int Clin Psychopharmacol. 2020;35:147–56.CrossRefPubMedPubMedCentral
15.
Kang SG, Cho SE, Na KS, et al. Clinical usefulness of amisulpride add-on therapy in schizophrenia patients without treatment response to second-generation antipsychotics. Clin Psychopharmacol Neurosci. 2021;19(1):117–24.CrossRefPubMedPubMedCentral
16.
Zangani C, Giordano B, Stein HC, et al. Efficacy of amisulpride for depressive symptoms in individuals with mental disorders: a systematic review and meta-analysis. Hum Psychopharmacol. 2021;36(6): e2801.CrossRefPubMedPubMedCentral
17.
Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134–42.CrossRefPubMedPubMedCentral
18.
Chen MH, Cheng CM, Gueorguieva R, et al. Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo-control study. Neuropsychopharmacology. 2019;44(12):2112–8.CrossRefPubMedPubMedCentral
19.
Walkery A, Leader LD, Cooke E, et al. Review of allopregnanolone agonist therapy for the treatment of depressive disorders. Drug Des Devel Ther. 2021;15:3017–26.CrossRefPubMedPubMedCentral
20.
Sartim AG, Guimarães FS, Joca SRL. Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex-possible involvement of 5-HT1A and CB1 receptors. Behav Brain Res. 2016;303:218–27.CrossRefPubMed
21.
Loebel A, Koblan KS, Tsai J, et al. A randomized, double-blind, placebo-controlled proof-of-concept trial to evaluate the efficacy and safety of non-racemic amisulpride (SEP-4199) for the treatment of bipolar I depression. J Affect Disord. 2022;296:549–58.CrossRefPubMed
22.
Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67:793–802.CrossRefPubMedPubMedCentral
23.
Zarate CA, Brutsche NE, Ibrahim L, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71:939–46.CrossRefPubMedPubMedCentral
24.
Grunebaum MF, Ellis SP, Keilp JG, et al. Ketamine versus midazolam in bipolar depression with suicidal thoughts: a pilot midazolam-controlled randomized clinical trial. Bipolar Disord. 2017;19:176–83.CrossRefPubMed
25.
Gunduz-Bruce H, Lasser R, Nandy I, et al. Open-label, phase 2 trial of the oral neuroactive steroid GABAA receptor positive allosteric modulator zuranolone in bipolar disorder I and II [abstract no. 182]. In: Psych Congerss Virtual Experience. 2020.
26.
Bauer IE, Green C, Colpo GD, et al. A double-blind, randomized, placebo-controlled study of aspirin and N-acetylcysteine as adjunctive treatments for bipolar depression. J Clin Psychiatry. 2018;80(1):18m12200.CrossRefPubMed
27.
Berk M, Turner A, Malhi GS, et al. A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo. BMC Med. 2019;17(1):18.CrossRefPubMedPubMedCentral
28.
Ellegaard PK, Licht RW, Nielsen RE, et al. The efficacy of adjunctive N-acetylcysteine in acute bipolar depression: a randomized placebo-controlled study. J Affect Disord. 2019;245:1043–51.CrossRefPubMed
29.
Magalhães PV, Dean OM, Bush AI, et al. N-acetylcysteine for major depressive episodes in bipolar disorder. Braz J Psychiatry. 2011;33(4):374–8.CrossRefPubMed
30.
Husain MI, Chaudhry IB, Khoso AB, et al. Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial. Lancet Psychiatry. 2020;7:515–27.CrossRefPubMed
31.
McIntyre RS, Subramaniapillai M, Lee Y, et al. Efficacy of adjunctive infliximab vs placebo in the treatment of adults with bipolar I/II depression: a randomized clinical trial. JAMA Psychiat. 2019;76:783–90.CrossRef
32.
Metadata
Title
Treat bipolar depression with atypical antipsychotics and mood stabilisers; new therapies require further study
Author
Simon Fung
Publication date
11-03-2024
Publisher
Springer International Publishing
Published in
Drugs & Therapy Perspectives / Issue 3/2024
Print ISSN: 1172-0360
Electronic ISSN: 1179-1977
DOI
https://doi.org/10.1007/s40267-024-01054-z

Other articles of this Issue 3/2024

Drugs & Therapy Perspectives 3/2024 Go to the issue

Adis Drug Q&A

Sparsentan in immunoglobulin A nephropathy: a profile of its use

Drug Reactions and Interactions

Be aware of the risks of nephrotoxicity when prescribing amoxicillin and third-generation cephalosporins

Disease Management

Treating paediatric Crohn’s disease is challenging but new treatments hold promise

Current Opinion

What is the role of pioglitazone for patients with type 2 diabetes in value-based care settings?

Practical Issues and Updates

Get on top of gout with a fresh look at treatment options

Correction

Correction to: Efanesoctocog alfa in hemophilia A: a profile of its use